KalVista Pharmaceuticals
KalVista Pharmaceuticals specializes in developing and commercializing oral protease inhibitors for diseases like hereditary angioedema (HAE), focusing on non-invasive treatments through its expertise in the kallikrein-kinin system.
Company Overview
KalVista Pharmaceuticals develops and commercializes oral protease inhibitor drugs. The company focuses on the kallikrein-kinin system and creates non-invasive treatment options for various diseases. Their global headquarters is in Cambridge, MA, USA, with additional locations in Porton Down, UK; Salt Lake City, UT, USA; Zug, Switzerland; and Tokyo, Japan. Combining scientific leadership with oral drug discovery expertise, KalVista aims to address unmet medical needs in areas such as hereditary angioedema (HAE), thrombosis, and inflammation.
Hereditary Angioedema (HAE) Treatments
KalVista Pharmaceuticals is committed to meeting the treatment needs for hereditary angioedema (HAE), a rare and potentially life-threatening condition. Their investigational product, sebetralstat, is an oral on-demand treatment for HAE. Sebetralstat has shown positive results in a pivotal Phase 3 clinical trial. Additionally, KalVista's pipeline includes preclinical programs for oral Factor XIIa inhibitors. These developments aim to expand the HAE product portfolio to include prophylactic treatment options.
Scientific Expertise in the Kallikrein-Kinin System
KalVista Pharmaceuticals leverages scientific leadership in the kallikrein-kinin system to develop innovative oral drugs. This system plays a significant role in the biology of diseases they target, including HAE, thrombosis, and inflammation. By focusing on oral drug discovery, KalVista aims to offer non-invasive treatment options, enhancing patient convenience and adherence to therapies.
Innovations and Pipeline
KalVista Pharmaceuticals' pipeline showcases their commitment to innovation. Besides HAE treatments, they are developing new therapies for other conditions like thrombosis and inflammation. By targeting diseases driven by the biology of the kallikrein-kinin system and Factor XIIa, KalVista aims to address unmet medical needs and improve patient outcomes with cutting-edge oral medications.
Global Presence
KalVista Pharmaceuticals operates on a global scale, with its corporate headquarters in Cambridge, MA, USA. Additionally, they have locations in Porton Down, UK; Salt Lake City, UT, USA; Zug, Switzerland; and Tokyo, Japan. This international presence enables KalVista to collaborate with global experts and leverage diverse resources in their mission to develop innovative therapeutic solutions.